|Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response|
P Jiang*, S Gu*, D Pan*, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, ...
Nature medicine 24 (10), 1550-1558, 2018
|Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism|
N Levaot, O Voytyuk, I Dimitriou, F Sircoulomb, A Chandrakumar, ...
Cell 147 (6), 1324-1339, 2011
|Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells|
G Chan, LS Cheung, W Yang, M Milyavsky, AD Sanders, S Gu, WX Hong, ...
Blood, The Journal of the American Society of Hematology 117 (16), 4253-4261, 2011
|Landscape of B cell immunity and related immune evasion in human cancers|
X Hu, J Zhang, J Wang, J Fu, T Li, X Zheng, B Wang, S Gu, P Jiang, J Fan, ...
Nature genetics 51 (3), 560-567, 2019
|Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis|
G Chan, S Gu, BG Neel
Blood, The Journal of the American Society of Hematology 121 (18), 3594-3598, 2013
|Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated RAF1 Mutants|
X Wu, J Yin, J Simpson, KH Kim, S Gu, JH Hong, P Bayliss, PH Backx, ...
Molecular and cellular biology 32 (19), 3872-3890, 2012
|Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1|
S Gu*, WW Chan*, G Mohi*, J Rosenbaum, A Sayad, Z Lu, C Virtanen, ...
Blood, The Journal of the American Society of Hematology 127 (14), 1803-1813, 2016
|SHP2 is required for BCR-ABL1-induced hematologic neoplasia|
S Gu, A Sayad, G Chan, W Yang, Z Lu, C Virtanen, RA Van Etten, ...
Leukemia 32 (1), 203-213, 2018
|Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles|
MA Hatlen, K Arora, V Vacic, EA Grabowska, W Liao, B Riley-Gillis, ...
Journal of Experimental Medicine 213 (1), 25-34, 2016
|Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer|
S Zhang, S Iyer, H Ran, I Dolgalev, S Gu, W Wei, CJR Foster, CA Loomis, ...
Cancer Discovery 11 (2), 362-383, 2021
|Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer|
C Wan, MP Keany, H Dong, LF Al-Alem, UM Pandya, S Lazo, K Boehnke, ...
Cancer research 81 (1), 158-173, 2021
|Immune receptor repertoires in pediatric and adult acute myeloid leukemia|
J Zhang, X Hu, J Wang, AD Sahu, D Cohen, L Song, Z Ouyang, J Fan, ...
Genome medicine 11 (1), 1-11, 2019
|High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia|
W Du, J He, W Zhou, S Shu, J Li, W Liu, Y Deng, C Lu, S Lin, Y Ma, Y He, ...
Journal of translational medicine 17 (1), 1-14, 2019
|Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors|
S Shi*, S Gu*, T Han, W Zhang, L Huang, Z Li, D Pan, J Fu, J Ge, M Brown, ...
Clinical Cancer Research 26 (22), 5990-6002, 2020
|CRISPR screens identify essential cell growth mediators in BRAF inhibitor-resistant melanoma|
Z Li, B Wang, S Gu, P Jiang, A Sahu, CH Chen, T Han, S Shi, X Wang, ...
Genomics, proteomics & bioinformatics 18 (1), 26-40, 2020
|Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade|
SS Gu*, W Zhang*, X Wang*, P Jiang*, N Traugh, Z Li, C Meyer, B Stewig, ...
Cancer Discovery 11 (6), 1524-1541, 2021
|Clonal tracing reveals diverse patterns of response to immune checkpoint blockade|
SS Gu*, X Wang*, X Hu*, P Jiang, Z Li, N Traugh, X Bu, Q Tang, C Wang, ...
Genome biology 21 (1), 1-28, 2020
|CoBRA: Containerized bioinformatics workflow for reproducible chip/atac-seq analysis-from differential peak calling to pathway analysis|
X Qiu, A Feit, A Feiglin, Y Xie, N Kesten, L Taing, J Perkins, N Zhou, S Gu, ...
|CoBRA: containerized bioinformatics workflow for reproducible ChIP/ATAC-seq analysis|
X Qiu, AS Feit, A Feiglin, Y Xie, N Kesten, L Taing, J Perkins, S Gu, Y Li, ...
Genomics, Proteomics & Bioinformatics, 2021
|MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets|
X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, J Larocque, ...